ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Nicotinamide (niacinamide): Drug information

Nicotinamide (niacinamide): Drug information
(For additional information see "Nicotinamide (niacinamide): Patient drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Pharmacologic Category
  • Vitamin, Water Soluble
Dosing: Adult
Pellagra

Pellagra (off-label use): Oral: 100 mg every 6 hours for several days (or until resolution of major signs and symptoms), followed by 50 mg every 8 to 12 hours until skin lesions heal (Hegyi 2004), or 500 mg once daily for several weeks (Jen 2010).

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

Dosing: Pediatric
Pellagra

Pellagra (off-label use): Oral: 10 to 50 mg every 6 hours until resolution of signs and symptoms (Hegyi 2004)

Dosing: Older Adult

Refer to adult dosing.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Tablet, Oral:

Generic: 100 mg, 500 mg

Tablet, Oral [preservative free]:

Generic: 500 mg [DSC]

Generic Equivalent Available: US

Yes

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Solution, Injection:

Generic: 100 mg/mL ([DSC])

Administration: Adult

Oral: Administer with food (preferred).

Use: Labeled Indications

Dietary supplement: For use as dietary supplement when niacinamide intake may be inadequate.

Use: Off-Label: Adult

Pellagra (treatment/prophylaxis)

Medication Safety Issues
Sound-alike/look-alike issues:

Niacinamide may be confused with niacin, niCARdipine

Adverse Reactions

The following adverse drug reactions are derived from product labeling unless otherwise specified.

Postmarketing: Hepatic: Abnormal hepatic function tests

Contraindications

Hypersensitivity to niacin, niacinamide, or any component of the formulation

Warnings/Precautions

Disease-related concerns:

• Diabetes: Use with caution in patients with diabetes mellitus; may interfere with glucose control.

• Gallbladder disease: Use with caution in patients with active gallbladder disease; can exacerbate.

• Gout: Use with caution in patients predisposed to gout.

• Peptic ulcer: Use with caution in patients with peptic ulcer.

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

HMG-CoA Reductase Inhibitors (Statins): Niacinamide may enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). Risk C: Monitor therapy

Pregnancy Considerations

Water-soluble vitamins cross the placenta (IOM 1998).

Mechanism of Action

Used by the body as a source of niacin; is a component of two coenzymes which is necessary for tissue respiration, lipid metabolism, and glycogenolysis; does not have hypolipidemia or vasodilating effects.

Pharmacokinetics

Half-life elimination: Dose-dependent: ~1.5 hours following a 1 g dose; ~4 hours following a 2 g dose; ~9 hours following a 6 g dose (Stratford 1992).

Time to peak, serum: ~1 to 3 hours (Stratford 1992).

Excretion: Urine (primarily as metabolites) (Stratford 1992).

Pricing: US

Tablets (Niacinamide Oral)

500 mg (per each): $0.03 - $0.04

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Brand Names: International
  • Bepella (CZ);
  • Farmobion Pp (IT);
  • Micril PP (PT);
  • Nicam (IE);
  • Nicobion (DE, FR, PY);
  • Nicotinamide (IT);
  • Nicotinsaureamid Jenapharm (DE);
  • Nicovitol (AT);
  • Papulex (GB);
  • Ucemine PP (BE, LU);
  • Vitamin B3 (AU);
  • Vitamina PP Angelini (IT);
  • Vitaminum PP (PL)


For country abbreviations used in Lexicomp (show table)
  1. Endur-Amide (niacinamide) [prescribing information]. Tualatin, OR: Endurance Products Company; received September 2018.
  2. Hegyi J, Schwartz RA, Hegyi V. Pellagra: dermatitis, dementia, and diarrhea. Int J Dermatol. 2004;43(1):1-5. doi:10.1111/j.1365-4632.2004.01959.x [PubMed 14693013]
  3. IOM (Institute of Medicine), Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin and Choline, Washington, DC: National Academy Press, 1998.
  4. Jen M, Yan AC. Syndromes associated with nutritional deficiency and excess. Clin Dermatol. 2010;28(6):669-685. doi:10.1016/j.clindermatol.2010.03.029 [PubMed 21034991]
  5. Niacinamide [prescribing information]. Livonia, MI: Rugby Laboratories; December 2019.
  6. Stratford MR, Rojas A, Hall DW, et al. Pharmacokinetics of nicotinamide and its effect on blood pressure, pulse and body temperature in normal human volunteers. Radiother Oncol. 1992;25(1):37-42. doi:10.1016/0167-8140(92)90193-x [PubMed 1410588]
Topic 9696 Version 121.0